SCHEMBL2912174

SCHEMBL2912174

O=C(NC(=S)Nc1ccc(Cc2ccccc2)cc1)c1cc2cnccc2o1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.62
MAPK1 P28482 3/20 0.59
LMNA P02545 3/20 0.59
HPGD P15428 2/20 0.59
MAPT P10636 5/20 0.57
NPC1 O15118 3/20 0.54
SMN1; SMN2 Q16637 4/20 0.53
KMT2A Q03164 3/20 0.53
POLB P06746 2/20 0.52
MEN1 O00255 2/20 0.52
GAA P10253 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
ALOX12 P18054 1/20 0.51
RAB9A P51151 1/20 0.50
HTT P42858 1/20 0.49
TSHR P16473 1/20 0.49
LSS P48449 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2910455 0.92 ALDH1A1 (0.63) ALDH1A1MAPK1LMNAHPGDMAPT
SCHEMBL2918585 0.89 ALDH1A1 (0.65) ALDH1A1MAPK1LMNAHPGDMAPT
SCHEMBL13956746 0.87 MAPT (0.74) ALDH1A1MAPTNPC1SMN1; SMN2KMT2A
SCHEMBL2910480 0.87 ALDH1A1 (0.61) ALDH1A1LMNAMAPTNPC1SMN1; SMN2
SCHEMBL2919490 0.83 ALDH1A1 (0.66) ALDH1A1MAPK1LMNAHPGDMAPT
SCHEMBL13175624 0.83 ALDH1A1 (0.54) ALDH1A1LMNAMAPTNPC1SMN1; SMN2
SCHEMBL2914457 0.82 ALDH1A1 (0.53) ALDH1A1LMNAMAPTNPC1SMN1; SMN2
SCHEMBL2917242 0.82 ALDH1A1 (0.53) ALDH1A1LMNAMAPTNPC1SMN1; SMN2
SCHEMBL2916577 0.82 ALDH1A1 (0.58) ALDH1A1MAPK1LMNAMAPTNPC1
SCHEMBL2910241 0.81 ALDH1A1 (0.62) ALDH1A1LMNAHPGDMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1709047-B1 AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS INC (US) 2010-09-01 EP claimed
US-7439374-B2 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2008-10-21 US claimed
CN-1946720-A Azabenzofuran substituted thioureas, inhibitors of viral replication ACHILLION PHARMACEUTICALS INC (US) 2007-04-11 CN claimed
US-20050228013-A1 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2005-10-13 US claimed
EP-1709047-B1 AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS INC (US) 2010-09-01 EP disclosed
EP-1709047-B1 AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS INC (US) 2010-09-01 EP disclosed
US-7439374-B2 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2008-10-21 US disclosed
US-7439374-B2 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2008-10-21 US disclosed
US-7439374-B2 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2008-10-21 US disclosed
US-20050228013-A1 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228013-A1 Azabenzofuran substituted thioureas; inhibitors of viral replication NAT1, PIGS, ADORA1 ALDH1A1 171/4885MAPK1 3423/4885LMNA 3932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.